{
  "catalysts": [
    {
      "ticker": "CAPR",
      "current_price": 24.31,
      "market_cap": "$620M",
      "conviction_score": 9,
      "thesis": "FDA request for the full HOPE-3 clinical study report (rather than a new trial) signals a clear, albeit slightly delayed, path to approval for Deramiocel.",
      "catalyst_details": "On Jan 20, 2026, Capricor provided a regulatory update stating the FDA requested the full HOPE-3 CSR to address the CRL; submission expected Feb 2026.",
      "absorption_status": "Initial knee-jerk reaction was mixed due to 'delay' fears, creating an entry window before the February submission catalyst.",
      "earnings_date": "2026-03-05",
      "relative_volume": "3.5x",
      "stop_loss_trigger": "$21.77 (1.5 ATR)",
      "sentiment": "Bullish",
      "prediction_market": "80% Approval Odds in 2026",
      "recency_proof": "Jan 20, 2026 Regulatory Update",
      "risk": "Further FDA delays post-submission.",
      "expected_upside": "40-50% upon BLA resubmission acceptance. | Target: $29.38",
      "mispricing_evidence": "Market penalized the stock for the timeline shift, ignoring the explicit confirmation that no new trials are needed.",
      "x_sentiment": "High chatter on $CAPR regarding FDA put",
      "atr_value": 1.69,
      "calculated_stop_loss": 21.77,
      "calculated_target": 29.38
    },
    {
      "ticker": "IONS",
      "current_price": 79.44,
      "market_cap": "$6.2B",
      "conviction_score": 8,
      "thesis": "European Commission approval of Donidalorsen (DAWNZERA) validates the HAE franchise, yet the stock remains range-bound as the market fixates on the US timeline.",
      "catalyst_details": "On Jan 21, 2026, Ionis announced EU Commission approval for DAWNZERA (donidalorsen) for hereditary angioedema (HAE).",
      "absorption_status": "Price action is muted despite the approval, suggesting the market is waiting for US FDA clarity; high relative volume indicates accumulation.",
      "earnings_date": "2026-02-18",
      "relative_volume": "1.8x",
      "stop_loss_trigger": "$74.67 (1.5 ATR)",
      "sentiment": "Bullish",
      "prediction_market": "75% Odds of US Approval in H1 2026",
      "recency_proof": "Jan 21, 2026 Press Release",
      "risk": "Commercial launch execution in EU.",
      "expected_upside": "15-20% on US regulatory read-through. | Target: $88.99",
      "mispricing_evidence": "Stock is trading at a discount to peers with approved HAE therapies despite superior administration profile.",
      "x_sentiment": "Rising interest in $IONS tag",
      "atr_value": 3.18,
      "calculated_stop_loss": 74.67,
      "calculated_target": 88.99
    },
    {
      "ticker": "LXRX",
      "current_price": 1.56,
      "market_cap": "$750M",
      "conviction_score": 7,
      "thesis": "Successful End-of-Phase 2 meeting with the FDA for pilavapadin de-risks the pivotal Phase 3 trial, a major milestone the market has yet to fully price in.",
      "catalyst_details": "On Jan 21, 2026, Lexicon announced the successful completion of an End-of-Phase 2 meeting with the FDA regarding pilavapadin for diabetic peripheral neuropathic pain.",
      "absorption_status": "Stock up only 3% on the news; lack of immediate double-digit pop suggests the significance of the regulatory alignment is underappreciated.",
      "earnings_date": "2026-02-26",
      "relative_volume": "2.1x",
      "stop_loss_trigger": "$1.43 (1.5 ATR)",
      "sentiment": "Bullish",
      "prediction_market": "N/A",
      "recency_proof": "Jan 21, 2026 Corporate Update",
      "risk": "Phase 3 execution costs and financing.",
      "expected_upside": "30% as Phase 3 starts. | Target: $1.83",
      "mispricing_evidence": "Current valuation reflects near-zero credit for the pain pipeline.",
      "x_sentiment": "Speculation on partnership talks",
      "atr_value": 0.09,
      "calculated_stop_loss": 1.43,
      "calculated_target": 1.83
    }
  ]
}